(Q42928535)

English

Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients

scientific article published on August 23, 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients (English)

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

immunohistochemistry

1 reference

based on heuristic

inferred from title

Beatrice Nardone

1

object named as

Beatrice Nardone

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20732960

21 June 2024

9

object named as

Dennis P. West

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20732960

21 June 2024

Mario E Lacouture

10

object named as

Mario E. Lacouture

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20732960

21 June 2024

author name string

Kimberly Nicholson

2

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Marissa Newman

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Joan Guitart

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Pedram Gerami

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Nicholas Talarico

6

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Alfred Rademaker

8

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Ximing J. Yang

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20732960

21 June 2024

language of work or name

0 references

publication date

23 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

full work available at URL

https://clincancerres.aacrjournals.org/content/clincanres/16/17/4452.full.pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20732960

21 June 2024

http://clincancerres.aacrjournals.org/cgi/content/abstract/16/17/4452

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20732960

21 June 2024

https://aacrjournals.org/clincancerres/article-pdf/16/17/4452/1991863/4452.pdf

Portable Document Format

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

4452-4460

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management

1

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Chemotherapeutic agents and the skin: An update

2

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy

5

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results

6

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Immunolocalization of Epidermal Growth Factor Receptors in Normal Developing Human Skin

7

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

ERK1/2 regulates epidermal chemokine expression and skin inflammation

10

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation

11

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

STAT3 activation accompanies keratinocyte differentiation

12

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment

13

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells

14

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Analysis of dermatologic events in patients with cancer treated with lapatinib.

15

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Erlotinib in previously treated non-small-cell lung cancer

16

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

17

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

18

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.

19

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies

20

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Cutaneous reactions related to systemic immunomodulators and targeted therapeutics

21

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.

22

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Lapatinib: current status and future directions in breast cancer

23

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death.

24

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

AKT1 provides an essential survival signal required for differentiation and stratification of primary human keratinocytes

25

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment

26

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity

27

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

28

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

The epidermal growth factor receptor system in skin repair and inflammation

29

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption

30

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

31

1 reference

10.1158/1078-0432.CCR-10-0421

https://api.crossref.org/works/10.1158/1078-0432.CCR-10-0421

21 June 2024

Identifiers

10.1158/1078-0432.CCR-10-0421

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42928535&oldid=2191644118"